Stem cell therapy holds great promise for improving and speeding up recovery after stroke. A UK Biotechnology Company is currently performing a ground-breaking first-in-man clinical trial to evaluate genetically engineered neural stem cells in stroke patients namely the PISCES study (Pilot Investigation of Stem Cells in Stroke). Following success so far in the phase 1 trial on safety, additional pre-clinical work is needed for the clinical development strategy with a view to commencing a Phase II efficacy study in 2013. The success of these stem cells in improving stroke outcome will have a massive impact on society and economy not just in the UK but world-wide.
|Effective start/end date||1/04/12 → 14/09/12|